273 related articles for article (PubMed ID: 24356817)
1. Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.
Bailey ML; O'Neil NJ; van Pel DM; Solomon DA; Waldman T; Hieter P
Mol Cancer Ther; 2014 Mar; 13(3):724-32. PubMed ID: 24356817
[TBL] [Abstract][Full Text] [Related]
2. A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers.
Mondal G; Stevers M; Goode B; Ashworth A; Solomon DA
Nat Commun; 2019 Apr; 10(1):1686. PubMed ID: 30975996
[TBL] [Abstract][Full Text] [Related]
3. STAG2 Regulates Homologous Recombination Repair and Sensitivity to ATM Inhibition.
Zhou J; Nie RC; He ZP; Cai XX; Chen JW; Lin WP; Yin YX; Xiang ZC; Zhu TC; Xie JJ; Zhang YC; Wang X; Lin P; Xie D; D'Andrea AD; Cai MY
Adv Sci (Weinh); 2023 Dec; 10(36):e2302494. PubMed ID: 37985839
[TBL] [Abstract][Full Text] [Related]
4. Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML.
Tothova Z; Valton AL; Gorelov RA; Vallurupalli M; Krill-Burger JM; Holmes A; Landers CC; Haydu JE; Malolepsza E; Hartigan C; Donahue M; Popova KD; Koochaki S; Venev SV; Rivera J; Chen E; Lage K; Schenone M; D'Andrea AD; Carr SA; Morgan EA; Dekker J; Ebert BL
JCI Insight; 2021 Feb; 6(3):. PubMed ID: 33351783
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
Bryant HE; Helleday T
Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
[TBL] [Abstract][Full Text] [Related]
6. Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer.
Liu Y; Xu H; Van der Jeught K; Li Y; Liu S; Zhang L; Fang Y; Zhang X; Radovich M; Schneider BP; He X; Huang C; Zhang C; Wan J; Ji G; Lu X
J Clin Invest; 2018 Jul; 128(7):2951-2965. PubMed ID: 29649003
[TBL] [Abstract][Full Text] [Related]
7. Synthetic lethality and cancer: cohesin and PARP at the replication fork.
O'Neil NJ; van Pel DM; Hieter P
Trends Genet; 2013 May; 29(5):290-7. PubMed ID: 23333522
[TBL] [Abstract][Full Text] [Related]
8. Intact Cohesion, Anaphase, and Chromosome Segregation in Human Cells Harboring Tumor-Derived Mutations in STAG2.
Kim JS; He X; Orr B; Wutz G; Hill V; Peters JM; Compton DA; Waldman T
PLoS Genet; 2016 Feb; 12(2):e1005865. PubMed ID: 26871722
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
[TBL] [Abstract][Full Text] [Related]
10. Cohesin mutations in human cancer.
Hill VK; Kim JS; Waldman T
Biochim Biophys Acta; 2016 Aug; 1866(1):1-11. PubMed ID: 27207471
[TBL] [Abstract][Full Text] [Related]
11. Expression of human poly (ADP-ribose) polymerase 1 in Saccharomyces cerevisiae: Effect on survival, homologous recombination and identification of genes involved in intracellular localization.
La Ferla M; Mercatanti A; Rocchi G; Lodovichi S; Cervelli T; Pignata L; Caligo MA; Galli A
Mutat Res; 2015 Apr; 774():14-24. PubMed ID: 25779917
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Tentori L; Portarena I; Torino F; Scerrati M; Navarra P; Graziani G
Glia; 2002 Oct; 40(1):44-54. PubMed ID: 12237842
[TBL] [Abstract][Full Text] [Related]
13. STAG1 vulnerabilities for exploiting cohesin synthetic lethality in STAG2-deficient cancers.
van der Lelij P; Newman JA; Lieb S; Jude J; Katis V; Hoffmann T; Hinterndorfer M; Bader G; Kraut N; Pearson MA; Peters JM; Zuber J; Gileadi O; Petronczki M
Life Sci Alliance; 2020 Jul; 3(7):. PubMed ID: 32467316
[TBL] [Abstract][Full Text] [Related]
14. Mutational inactivation of STAG2 causes aneuploidy in human cancer.
Solomon DA; Kim T; Diaz-Martinez LA; Fair J; Elkahloun AG; Harris BT; Toretsky JA; Rosenberg SA; Shukla N; Ladanyi M; Samuels Y; James CD; Yu H; Kim JS; Waldman T
Science; 2011 Aug; 333(6045):1039-43. PubMed ID: 21852505
[TBL] [Abstract][Full Text] [Related]
15. Paralogous synthetic lethality underlies genetic dependencies of the cancer-mutated gene
Bailey ML; Tieu D; Habsid A; Tong AHY; Chan K; Moffat J; Hieter P
Life Sci Alliance; 2021 Nov; 4(11):. PubMed ID: 34462321
[No Abstract] [Full Text] [Related]
16. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.
Vilar E; Bartnik CM; Stenzel SL; Raskin L; Ahn J; Moreno V; Mukherjee B; Iniesta MD; Morgan MA; Rennert G; Gruber SB
Cancer Res; 2011 Apr; 71(7):2632-42. PubMed ID: 21300766
[TBL] [Abstract][Full Text] [Related]
17. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
18. EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.
Pfäffle HN; Wang M; Gheorghiu L; Ferraiolo N; Greninger P; Borgmann K; Settleman J; Benes CH; Sequist LV; Zou L; Willers H
Cancer Res; 2013 Oct; 73(20):6254-63. PubMed ID: 23966292
[TBL] [Abstract][Full Text] [Related]
19. Cohesin mutations in myeloid malignancies made simple.
Viny AD; Levine RL
Curr Opin Hematol; 2018 Mar; 25(2):61-66. PubMed ID: 29278534
[TBL] [Abstract][Full Text] [Related]
20. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M
PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
